Exhibit 10.10
AMENDED AND RESTATED EMPLOYMENT AGREEMENT
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the
“Agreement”), is entered into effective as of July 31, 2024 (the “Effective Date”), by and between Sensei Biotherapeutics, Inc. (the “Company”) and Christopher Gerry (the “Executive”). This Agreement amends, restates, and supersedes in its entirety the Employment Agreement between the Company and Executive, dated July 18, 2022 (the “Prior Agreement”).
The Company desires to continue to employ Executive, now in the capacity of full-time SVP, General Counsel, pursuant to the terms of this Agreement and, in connection therewith, to compensate Executive for Executive’s personal services to the Company; and
Executive wishes to continue to be employed by the Company and provide personal services to the Company in return for certain compensation.
Accordingly, in consideration of the mutual promises and covenants contained herein, the parties agree to the following:
be interpreted, adopted, revised or deleted from time to time in the Company’s sole discretion. Executive will be eligible to participate on the same basis as similarly situated employees in the Company’s benefit plans in effect from time to time during Executive’s employment. All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions of such plan. The Company reserves the right to change, alter, or terminate any
Exhibit 10.10
benefit plan in its sole discretion. Notwithstanding the foregoing, in the event that the terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement shall control.
reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.
Exhibit 10.10
continued employment and in consideration of the benefits that Executive is eligible to receive under this Agreement, including, but not limited to, the compensation offered and provided to Executive hereunder, and as an express condition of the offer and provision of such additional compensation to Executive, Executive agrees to continue to abide by that certain Confidential Information, Invention Assignment, Non-Solicitation and Non-Competition Agreement (the “Covenants Agreement”) previously entered into between the Company and Executive and made effective as of July 18, 2022.
Exhibit 10.10
Exhibit 10.10
Exhibit 10.10
Section 6.2 are in lieu of, and not in addition to, any benefits to which Executive may otherwise be entitled under any Company severance plan, policy or program.
Subject to Section 6.3(b) below, the Company shall have the right to terminate Executive’s employment with the Company at any time for Cause by giving notice as described in Section 6.7 of this Agreement.
Exhibit 10.10
times have the right, upon written notice to the Executive, to terminate this Agreement based on Executive’s Disability (as defined below). Termination by the Company of Executive’s employment based on “Disability” shall mean termination because Executive is unable due to a physical or mental condition to perform the essential functions of Executive’s position with or without reasonable accommodation for six (6) months in the aggregate during any twelve (12) month period or based on the written certification by two licensed physicians of the likely continuation of such condition for such period. This definition shall be interpreted and applied consistent with the Americans with Disabilities Act, the Family and Medical Leave Act, and other applicable law. In the event Executive’s employment is terminated based on Executive’s Disability, Executive will not receive the Non-CIC Severance Benefits, the CIC Severance Benefits, or any other severance compensation or benefit, except that, pursuant to the Company’s standard payroll policies, the Company shall provide to Executive the Accrued Obligations.
Exhibit 10.10
Exhibit 10.10
Exhibit 10.10
(B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future
events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.
Exhibit 10.10
Exhibit 10.10
Exhibit 10.10
[SIGNATURES TO FOLLOW ON NEXT PAGE]
IN WITNESS WHEREOF, the parties have executed this Employment Agreement on the day and year first written above.
SENSEI BIOTHERAPEUTICS, INC.
By: John Celebi
/s/ John Celebi
Its: President and CEO
Executive: /s/ Christopher Gerry
Christopher Gerry
Date: 08/01/2024